First Implantation Of TYRX® AIGISRx® R Fully Resorbable Antibacterial Envelope

In short

TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, has issued a press release confirming that the first implantation of its new AIGISRx® R Fully Resorbable Antibacterial Envelope has taken place.


The AIGISRx R Antibacterial Envelope is specifically designed to hold Electronic Implantable Devices (EIDs), such as pacemakers and defibrillators securely in place in the body , while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.

The envelope contains rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of Cardiac Implantable Electronic Devices (CIED) infections, including “superbugs” such as methicillin-resistant S. aureus (MRSA).

TYRX announced on January 31, 2013 that it had received a license from Health Canada to market its AIGISRx R Fully Resorbable technology.

The implantation was performed at the Quebec Heart and Lung Institute in Quebec City, Canada by Dr. François Philippon.

Physician comments

“Surgical site infections are on the rise and have profound consequences to the patient with regard to having to spend extra time in the hospital, having to undergo additional surgical procedures, and having significant increases in morbidity and mortality. They are also very expensive to treat,” stated Dr. Philippon, cardiac electrophysiologist at the Quebec Heart and Lung Institute. “I found implantation of the fully resorbable envelope to be very straightforward and believe that the combination of stabilization and locally delivered antibiotics provided by the product will be of great potential benefit to our patients.”

Company comments

“We are very excited to have the world’s first AIGISRx R Antibacterial Envelope implanted at the Quebec Heart and Lung Institute,” commented Robert White, TYRX President and Chief Executive Officer. “The AIGISRx R includes all of the advantages of the original AIGISRx, such as stability and infection reduction, but now with the added benefit of full resorption in approximately 9 weeks.”

Source: TYRX, Inc., Business Wire